Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.12-0.45 (-5.94%)
At close: 1:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close7.57
Open7.10
Bid6.70 x 800
Ask9.79 x 800
Day's Range7.00 - 7.12
52 Week Range6.97 - 35.00
Volume967
Avg. Volume1,974
Market Cap40.526M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
Inf% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ADXN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Addex Therapeutics Ltd
    Daily – Vickers Top Insider Picks for 11/04/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    23 days agoArgus Research
View more
  • GlobeNewswire

    Addex to Present at the Virtual German Equity Forum

    Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery – Biology, Dr Robert Lütjens, will be attending the virtual German Equity Forum to be held November 22 – 24, 2021. Mr Dyer’s presentation is scheduled for November 23, 2021 at 08:00 EST / 14:00 CET. In his presentation, Mr Dyer will provide a c

  • GlobeNewswire

    Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

    Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference. In his presentation, which is scheduled for today, November 15, 2021 at 08:30 EST / 14:30 CET, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video prese

  • GlobeNewswire

    Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149

    Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed Phase 1 studies in Japan with

Advertisement
Advertisement